116 related articles for article (PubMed ID: 35790273)
1. Biomarker Profiling Revealed Carcinoembryonic Antigen as a Target of Artesunate in a Ductal Breast Cancer Patient.
Saeed MEM; Drif AI; Efferth T
Anticancer Res; 2022 Jul; 42(7):3483-3494. PubMed ID: 35790273
[TBL] [Abstract][Full Text] [Related]
2. Biomarker Expression Profiling in Cervix Carcinoma Biopsies Unravels WT1 as a Target of Artesunate.
Saeed MEM; Cives-Losada C; Efferth T
Cancer Genomics Proteomics; 2022; 19(6):727-739. PubMed ID: 36316038
[TBL] [Abstract][Full Text] [Related]
3. Long-term add-on therapy (compassionate use) with oral artesunate in patients with metastatic breast cancer after participating in a phase I study (ARTIC M33/2).
von Hagens C; Walter-Sack I; Goeckenjan M; Storch-Hagenlocher B; Sertel S; Elsässer M; Remppis BA; Munzinger J; Edler L; Efferth T; Schneeweiss A; Strowitzki T
Phytomedicine; 2019 Feb; 54():140-148. PubMed ID: 30668363
[TBL] [Abstract][Full Text] [Related]
4. Prognostic relevance of carcinoembryonic antigen and estrogen receptor status in breast cancer patients.
Esteban JM; Felder B; Ahn C; Simpson JF; Battifora H; Shively JE
Cancer; 1994 Sep; 74(5):1575-83. PubMed ID: 7914825
[TBL] [Abstract][Full Text] [Related]
5. Independent prognostic impact of preoperative serum carcinoembryonic antigen and cancer antigen 15-3 levels for early breast cancer subtypes.
Imamura M; Morimoto T; Nomura T; Michishita S; Nishimukai A; Higuchi T; Fujimoto Y; Miyagawa Y; Kira A; Murase K; Araki K; Takatsuka Y; Oh K; Masai Y; Akazawa K; Miyoshi Y
World J Surg Oncol; 2018 Feb; 16(1):26. PubMed ID: 29433529
[TBL] [Abstract][Full Text] [Related]
6. An updated evaluation of serum sHER2, CA15.3, and CEA levels as biomarkers for the response of patients with metastatic breast cancer to trastuzumab-based therapies.
Perrier A; Boelle PY; Chrétien Y; Gligorov J; Lotz JP; Brault D; Comperat E; Lefèvre G; Boissan M
PLoS One; 2020; 15(1):e0227356. PubMed ID: 31910438
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of circulating tumor cells (CTCs) with respect to optimal cut-off value and tumor markers in advanced/metastatic breast cancer.
Shiomi-Mouri Y; Kousaka J; Ando T; Tetsuka R; Nakano S; Yoshida M; Fujii K; Akizuki M; Imai T; Fukutomi T; Kobayashi K
Breast Cancer; 2016 Jan; 23(1):120-127. PubMed ID: 24906662
[TBL] [Abstract][Full Text] [Related]
8. Variations in tumor marker levels in metastatic breast cancer patients according to tumor subtypes.
Kos T; Aksoy S; Sendur MA; Arik Z; Civelek B; Kandemir N; Ozdemir NY; Zengin N; Altundag K
J BUON; 2013; 18(3):608-13. PubMed ID: 24065471
[TBL] [Abstract][Full Text] [Related]
9. Prospective evaluation of carcinoembryonic antigen (CEA) and carbohydrate antigen 15.3 (CA 15.3) in patients with primary locoregional breast cancer.
Molina R; Auge JM; Farrus B; Zanón G; Pahisa J; Muñoz M; Torne A; Filella X; Escudero JM; Fernandez P; Velasco M
Clin Chem; 2010 Jul; 56(7):1148-57. PubMed ID: 20472825
[TBL] [Abstract][Full Text] [Related]
10. Comparative evaluation of serum CA 195 and carcinoembryonic antigen in metastatic carcinoma.
Verdi CJ; Ahmann FR; Schifman RB; Elvick AL; Ahmann ME; Marx PC
Cancer; 1993 Jun; 71(11):3625-32. PubMed ID: 8490911
[TBL] [Abstract][Full Text] [Related]
11. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
12. Long-term prognostic study of carcinoembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA 15-3) in breast cancer.
Uehara M; Kinoshita T; Hojo T; Akashi-Tanaka S; Iwamoto E; Fukutomi T
Int J Clin Oncol; 2008 Oct; 13(5):447-51. PubMed ID: 18946756
[TBL] [Abstract][Full Text] [Related]
13. HER-2 gene amplification, serum nucleosomes, CEA and CA15.3 tumor markers in breast cancer patients.
Zeiwar MM; Zaki SM; Mohammad LA; Zidan AA; El Nagar MR
Egypt J Immunol; 2007; 14(2):29-41. PubMed ID: 20306655
[TBL] [Abstract][Full Text] [Related]
14. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.
Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J
Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854
[TBL] [Abstract][Full Text] [Related]
15. Relationship between preoperative serum CA 15-3 and CEA levels and clinicopathological parameters in breast cancer.
Moazzezy N; Farahany TZ; Oloomi M; Bouzari S
Asian Pac J Cancer Prev; 2014; 15(4):1685-8. PubMed ID: 24641390
[TBL] [Abstract][Full Text] [Related]
16. Relationship between Hypoxia and Carcinoembryonic Antigen and Upregulated Carcinoembryonic Antigen is Associated with Poor Prognosis in Breast Cancer Patients.
Liu Y; Zuo D; Huang C; Zhao M; Hou Y; Chang J; Ren L
Clin Lab; 2019 Dec; 65(12):. PubMed ID: 31850706
[TBL] [Abstract][Full Text] [Related]
17. The utility of serum tumor markers CEA and CA 15-3 for breast cancer prognosis and their association with clinicopathological parameters.
Uygur MM; Gümüş M
Cancer Treat Res Commun; 2021; 28():100402. PubMed ID: 34082362
[TBL] [Abstract][Full Text] [Related]
18. Activity of Artemisia annua and artemisinin derivatives, in prostate carcinoma.
Michaelsen FW; Saeed ME; Schwarzkopf J; Efferth T
Phytomedicine; 2015 Dec; 22(14):1223-31. PubMed ID: 26655404
[TBL] [Abstract][Full Text] [Related]
19. Comparison of bone scintigraphy with serum tumor markers of CA 15-3 and carcinoembryonic antigen in patients with breast carcinoma.
Gedik GK; Kiratli PO; Tascioglu B; Aras T
Saudi Med J; 2006 Mar; 27(3):317-22. PubMed ID: 16532090
[TBL] [Abstract][Full Text] [Related]
20. Maspin and mammaglobin genes are specific markers for RT-PCR detection of minimal residual disease in patients with breast cancer.
Corradini P; Voena C; Astolfi M; Delloro S; Pilotti S; Arrigoni G; Bregni M; Pileri A; Gianni AM
Ann Oncol; 2001 Dec; 12(12):1693-8. PubMed ID: 11843246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
